226 related articles for article (PubMed ID: 9039294)
21. Increased expression of collagen types I and III in human skin as a consequence of radiotherapy.
Riekki R; Parikka M; Jukkola A; Salo T; Risteli J; Oikarinen A
Arch Dermatol Res; 2002 Jul; 294(4):178-84. PubMed ID: 12111348
[TBL] [Abstract][Full Text] [Related]
22. Procollagen Type I and III Aminoterminal Propeptide Levels and Severity of Interstitial Lung Disease in Mexican Women With Progressive Systemic Sclerosis.
Gonzalez-Lopez L; Rocha-Muñoz AD; Olivas-Flores EM; Garcia-Gonzalez A; Peguero-Gómez AR; Flores-Navarro J; Villa-Manzano AI; Zavaleta-Muñiz SA; Salazar-Paramo M; Mejía M; Juárez-Contreras P; Vazquez-Del Mercado M; Cardona-Muñoz EG; Trujillo-Hernández B; Nava-Zavala AH; Gamez-Nava JI
Arch Bronconeumol; 2015 Sep; 51(9):440-8. PubMed ID: 25301411
[TBL] [Abstract][Full Text] [Related]
23. Hyaluronan and procollagen type III aminoterminal peptide in serum and bronchoalveolar lavage fluid from patients with pulmonary fibrosis.
Milman N; Kristensen MS; Bentsen K
APMIS; 1995 Oct; 103(10):749-54. PubMed ID: 8534435
[TBL] [Abstract][Full Text] [Related]
24. Type III and type I procollagen markers in fibrosing alveolitis.
Lammi L; Ryhänen L; Lakari E; Risteli J; Pääkkö P; Kahlos K; Lähde S; Kinnula V
Am J Respir Crit Care Med; 1999 Mar; 159(3):818-23. PubMed ID: 10051256
[TBL] [Abstract][Full Text] [Related]
25. Plasma endothelin and the aminoterminal propeptide of type III procollagen (PIIINP) in systemic sclerosis.
Zachariae H; Heickendorff L; Bjerring P; Halkier-Sørensen L; Søndergaard K
Acta Derm Venereol; 1994 Sep; 74(5):368-70. PubMed ID: 7817674
[TBL] [Abstract][Full Text] [Related]
26. The production of collagen and the activity of mast-cell chymase increase in human skin after irradiation therapy.
Riekki R; Harvima IT; Jukkola A; Risteli J; Oikarinen A
Exp Dermatol; 2004 Jun; 13(6):364-71. PubMed ID: 15186323
[TBL] [Abstract][Full Text] [Related]
27. Serum concentrations of laminin P1 and aminoterminal propeptide of type III procollagen in sickle cell disease.
Bolarin DM; Swerdlow P; Wallace AM; Littsey L
Haematologia (Budap); 1998; 29(1):51-8. PubMed ID: 9704258
[TBL] [Abstract][Full Text] [Related]
28. Soluble intercellular adhesion molecule-1 (sICAM-1) and soluble interleukin-2 receptors (sIL-2R) in scleroderma skin.
Søndergaard K; Stengaard-Pedersen K; Zachariae H; Heickendorff L; Deleuran M; Deleuran B
Br J Rheumatol; 1998 Mar; 37(3):304-10. PubMed ID: 9566672
[TBL] [Abstract][Full Text] [Related]
29. Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin.
Trocme C; Leroy V; Sturm N; Hilleret MN; Bottari S; Morel F; Zarski JP
J Viral Hepat; 2006 Oct; 13(10):643-51. PubMed ID: 16970595
[TBL] [Abstract][Full Text] [Related]
30. Serum concentration of procollagen type I carboxyterminal propeptide in localized scleroderma.
Kikuchi K; Sato S; Kadono T; Ihn H; Takehara K
Arch Dermatol; 1994 Oct; 130(10):1269-72. PubMed ID: 7944508
[TBL] [Abstract][Full Text] [Related]
31. Aminoterminal propeptide of type III procollagen: a marker of hepatic fibrosis after bile duct obstruction in the monkey.
Ruf G; Mappes HJ; Koch H; Baumgartner U; Hagmann W; Farthmann EH
Hepatogastroenterology; 1996; 43(7):121-6. PubMed ID: 8682446
[TBL] [Abstract][Full Text] [Related]
32. Different effects of thyroid disease on serum levels of procollagen III N-peptide and hyaluronic acid.
Faber J; Hørslev-Petersen K; Perrild H; Lorenzen I
J Clin Endocrinol Metab; 1990 Oct; 71(4):1016-21. PubMed ID: 2401705
[TBL] [Abstract][Full Text] [Related]
33. Aminoterminal propeptide of type III procollagen and hyaluronan in patients with primary biliary cirrhosis: markers of fibrosis in primary biliary cirrhosis.
Remmel T; Remmel H; Salupere V
J Gastroenterol Hepatol; 1996 Nov; 11(11):1016-20. PubMed ID: 8985819
[TBL] [Abstract][Full Text] [Related]
34. Collagen synthesis in intact skin is suppressed during wound healing.
Ihlberg L; Haukipuro K; Risteli L; Oikarinen A; Kairaluoma MI; Risteli J
Ann Surg; 1993 Apr; 217(4):397-403. PubMed ID: 8466311
[TBL] [Abstract][Full Text] [Related]
35. Type III procollagen N-terminal propeptide, soluble interleukin-2 receptor, and von Willebrand factor in systemic sclerosis.
Lee YJ; Shin KC; Kang SW; Lee EB; Kim HA; Song YW
Clin Exp Rheumatol; 2001; 19(1):69-74. PubMed ID: 11247328
[TBL] [Abstract][Full Text] [Related]
36. Value of fibrosis markers for staging liver fibrosis in patients with precirrhotic alcoholic liver disease.
Lieber CS; Weiss DG; Paronetto F;
Alcohol Clin Exp Res; 2008 Jun; 32(6):1031-9. PubMed ID: 18422837
[TBL] [Abstract][Full Text] [Related]
37. Carboxyterminal type I procollagen peptide concentrations in systemic sclerosis: higher levels in early diffuse disease.
Scheja A; Hellmer G; Wollheim FA; Akesson A
Br J Rheumatol; 1993 Jan; 32(1):59-62. PubMed ID: 8422562
[TBL] [Abstract][Full Text] [Related]
38. A new method to measure type I and III collagen synthesis in human skin in vivo: demonstration of decreased collagen synthesis after topical glucocorticoid treatment.
Oikarinen A; Autio P; Kiistala U; Risteli L; Risteli J
J Invest Dermatol; 1992 Feb; 98(2):220-5. PubMed ID: 1732386
[TBL] [Abstract][Full Text] [Related]
39. Biochemical markers of types I and III collagen and limited joint mobility in type 1 diabetic patients.
Arkkila PE; Koskinen PJ; Kantola IM; Rönnemaa T; Seppänen E; Viikari JS
Acta Diabetol; 2003 Dec; 40(4):151-5. PubMed ID: 14740273
[TBL] [Abstract][Full Text] [Related]
40. Aberrant serum hyaluronan and hyaluronidase levels in scleroderma.
Neudecker BA; Stern R; Connolly MK
Br J Dermatol; 2004 Mar; 150(3):469-76. PubMed ID: 15030329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
